365NEWSX
365NEWSX
Subscribe

Welcome

Vaccine Stocks: Will Johnson & Johnson's Coronavirus Vaccine Undercut Pfizer, Moderna - Investor's Business Daily

Vaccine Stocks: Will Johnson & Johnson's Coronavirus Vaccine Undercut Pfizer, Moderna - Investor's Business Daily

Jan 25, 2021 1 min, 36 secs

Johnson & Johnson (JNJ) is expected imminently to release test results for its coronavirus vaccine in a move that could rock vaccine stocks Pfizer (PFE) and Moderna (MRNA).

In order to gain traction, a new coronavirus vaccine must have a benefit over those drugs, Brad Loncar, chief executive of Loncar Investments, told Investor's Business Daily.

"We always knew the mRNA vaccines — from a first-generation standpoint — wouldn't be perfect because we always knew they would need two doses," he said.

Moderna shares soared 12.2% to 147 after the company said its vaccine generated neutralizing antibodies against variants of the coronavirus in the U.K.

It's easy to see how a single-injection drug from vaccine stock Johnson & Johnson could offer a benefit over double-dose regimens from Pfizer with development partner BioNTech (BNTX), and Moderna.

On top of that, the Covid shot from vaccine stocks Pfizer and BioNTech must be transported and stored in ultracold temperatures.

So, if Johnson & Johnson can't beat these vaccine stocks on effectiveness, it must do so through an easy route of administration or through better stability.

For that reason, Loncar says Johnson & Johnson's one-shot strategy "has much more wiggle room." If the coronavirus vaccine is 70%-80% effective, "that would definitely be a win," he said.

The same can't be said for vaccine stock AstraZeneca (AZN), however.

In late December, AstraZeneca said its coronavirus vaccine was 70.4% effective, on average, across two dosing regimens.

News from vaccine stocks Johnson & Johnson, AstraZeneca and Novavax (NVAX) — all in Phase 3 testing now — will inevitably have an impact on Pfizer and Moderna, Needham analyst Alan Carr says.

Pfizer and Moderna have the benefit of being first to market with highly effective drugs, he said.

"The biggest thing is: Are Moderna and Pfizer going to be the only game in town?" Loncar said.

Merck stock recovered from a dip Monday after the company scrapped development of two coronavirus vaccines the company said were...

Summarized by 365NEWSX ROBOTS

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED